Publications
ASCO 2023 Poster: Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
ASCO 2023: Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
ASCO 2023: Phase 1, randomized, open-label, single-dose, crossover study to evaluate the bioequivalence of four formulations of oral rivoceranib tablets in healthy subjects.
AACR 2023: Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR-2 Inhibitor
AACR 2023: Effect of Rivoceranib on the Pharmacokinetics of Cytochrome P450 Enzyme Substrates: A Phase 1 Trial in Healthy Volunteers
ESMO 2022: Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib Plus Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
ASCO 2022: A Phase 2 Study of the Oral Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor, Rivoceranib, for Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (ACC)
Gynecologic Oncology: Phase 3 Publication of Efficacy & Safety Results Comparing Paclitaxel Micellar & Cremophor EL-Paclitaxel
ASCO Annual Meeting 2020 Poster Report of Rivoceranib in Recurrent or Metastatic Adenoid Cystic Carcinoma
ASCO-SITC Clinical Immuno-Oncology Symposium 2019 Poster Report of Rivoceranib in Combination with Nivolumab
AACR 2018 Poster Report of Preclinical Rivoceranib (Apatinib) Combination with Immunotherapy
ACCP 2017 Poster of a Phase 1 Ethnic PK Study
ASCO 2017 Poster Report of Apatinib Phase III Trial in Progress
ESMO 2016 Poster Report of Apatinib Phase II Study Results
